Bristol-Myers Squibb Appoints Mike Burgess M.D., Ph.D. Senior Vice President, Discovery Medicine and Clinical Pharmacology

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Mike Burgess M.D., Ph.D. has joined the Company as senior vice president, Discovery Medicine and Clinical Pharmacology. He will report to Francis Cuss, MB BChir, FRCP, senior vice president, Research, R&D, Bristol-Myers Squibb, and will be a member of the Research Senior Leadership Team.

“Mike’s broad clinical expertise, cross-therapeutic global team leadership and proven operational excellence will enable Bristol-Myers Squibb to continue to execute its strategy of ensuring sustainable delivery of an innovative pipeline of new medicines for patients.”

“As a physician scientist with a Ph.D. in molecular biology, clinical experience in pediatrics and pediatric oncology, and extensive pharmaceutical industry and leadership experience, I believe Mike will be an important addition to our research and development organization,” said Dr. Cuss. “Mike’s broad clinical expertise, cross-therapeutic global team leadership and proven operational excellence will enable Bristol-Myers Squibb to continue to execute its strategy of ensuring sustainable delivery of an innovative pipeline of new medicines for patients.”

Before joining Bristol-Myers Squibb, Dr. Burgess was interim head of Hoffman La-Roche’s Pharma Research and Early Development organization. Prior to that he led the Hoffman La-Roche Oncology Discovery and Translational Area, one of five disease-focused organizations, and at the same time served as head of Global Large Molecule Research. Before joining Hoffman La-Roche, Dr. Burgess was at Eli Lilly and Company as a Medical Fellow. He received his medical training and Ph.D. from the University of Bristol, U.K., and is a member of the Royal College of Physicians and of the Royal College of Pediatrics and Child Health.

“I am excited by the opportunity to join Bristol-Myers Squibb and its Research Leadership Team,” said Dr. Burgess. “Bristol-Myers Squibb is well known and respected for its innovative pipeline and approach to discovering and developing new medicines. I am looking forward to joining this committed team and continuing to drive research that delivers a differentiated pipeline of potential new medicines.”

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.